THANKS for the analysis. The positive, is they are generating income.

WAS hoping for a deep dive into the 1-SA, Any opinion? I'm not good at legalese.

volume from the opening? over 7m? things that make you go UMMMM!

SAD. I GUESS ITS A WRAP.

I continue to see small buys on this, any insight?

Xcelerate, Inc. Announces That ESN Group, Inc. Has Been
Approved as a Vendor to Army & Air Force Exchange Service
Mauldin, SC., September 14, 2023 --Xcelerate, Inc. (OTCQB: "XCRT”) today
announced that ESN Group, Inc., a subsidiary of Xcelerate, has been designated as
an approved vendor to the Army & Air Force Exchange Service (“AAFES”). AAFES,
also known as PX and Post Exchange, provides goods and services to more than
3,000 U.S. Army and Air Force installations across 50 U.S. states and more than 30
countries as well as online. The approval is for 21 ESN products including all seven
Ceramedx® products. Ceramedx® is the first plant-based ceramide therapy system
developed in consultation with dermatologists for dry, sensitive skin and conditions
such as eczema.
“This approval is the result of a joint effort between Jay Kline, President of ESN and
John Porter of Product Sector, our recently engaged marketing partner. I am
amazed and appreciative of how much progress has been made by Jay and John
since announcing our agreement in August and look forward to their efforts to
rapidly expand market penetration of both the Ceramedx and Earth Science Beauty
product lines. This partnership ideally positions the Company to accelerate revenue
opportunities” said Mike O’Shea, Xcelerate’s CEO.
Investors and stakeholders are encouraged to stay updated on the latest
developments by visiting the company’s website at https://xcelerate.global/.
ABOUT XCELERATE INC.
In May 2020, Xcelerate commenced implementation of a new business plan that encompasses
two separate but related businesses within the medical industry, including (i) owning and
licensing the rights to various forms of medical equipment and portfolio of patents, patents
pending and technology licenses and (ii) development of virtual health technology to assist
patients in developing countries obtain medical care by extending the reach of physicians
through the use of that technology. For more information visit www.xcelerate.global or contact
us at 854-900-2020 or email info@xcelerate.global.

5M VOLUME SO FAR TODAY. Is the Phoenix rising?

The CEO has so many shares of his own, unthinkable to seemingly abandon this stock.

OTC Disclosure & News Service ------- only part of article----read ret on otc markets
Xcelerate, Inc. Announces PTO and PCT Filings For Surgical DevicesPress Release | 04/20/2023

MAULDIN, SC / ACCESSWIRE / April 20, 2023 / Xcelerate, Inc. (OTCQB:XCRT) announced today it filed two utility patent applications under application numbers 18/187,352 and 18/189,441. Additionally, corresponding PCT applications were filed under PCT/US2023/015755 and PCT/US2023/016194. Both applications are claiming priority to Xcelerate's patent application "Surgical Tools with Targeting Guidance", filed under application number 63/323,112 on March 24th, 2022.

MAUDLIN, SC / ACCESSWIRE / April 12, 2023 / Xcelerate, Inc. XCRT
announced today that it had completed its' due diligence and has entered into a binding agreement to acquire a controlling interest in ESN Group, Inc. and its' portfolio of health care and skin care products. The agreement calls for payment of $350,000 cash, the issuance of restricted Xcelerate stock, assumption of debt and employment agreements for key staff. The acquisition is expected to close no later than June 30, 2023.

"This transaction is another significant milestone in our value creation plan. On closing, Xcelerate will realize an immediate, ongoing revenue stream and, together with the management team from ESN and other significant partners, we will initiate a program to expand our product offering to mass merchant outlets and government agencies who have already expressed interest. The acquisition will also provide Xcelerate with the industry connections and management talent to further our previously announced goal of developing additional over-the-counter healthcare products based on our existing patent portfolio" said Mike O'Shea, Xcelerate CEO

anyone, have a clue about this stock/company?

lookin good. IMHO STILL A BARGAIN.

Xcelerate, Inc. to Develop Consumer Healthcare Products

Xcelerate, Inc.
Tue, August 30, 2022 at 8:30 AM
In this article:

XCRT
+11.67%

Xcelerate, Inc. to Develop Consumer Healthcare Products Based on Its Current Patent Portfolio

MAULDIN, SC / ACCESSWIRE / August 30, 2022 / Xcelerate, Inc. (OTCQB:XCRT) today announced that it had begun an initiative to identify marketing/manufacturing partners to assist in the development of over-the-counter healthcare products based on its existing patent portfolio.
Xcelerate, Inc., Tuesday, August 30, 2022, Press release picture
Xcelerate, Inc., Tuesday, August 30, 2022, Press release picture

"As previously announced, Xcelerate has recently acquired a portfolio of licensed and patented IP from HS Pharmaceutical, representing the culmination of years of research by world renowned scientists and institutions as well as the investment of millions of dollars in development costs. Recent meetings between our advisors and the staff and scientists at HS Pharmaceuticals have resulted in the decision to pursue the development and marketing of certain of these patented technologies as over-the-counter healthcare products. We believe that we will be able to fast track one or more products that will provide revenue potential for Xcelerate in the near term," said Xcelerate CEO Michael O'Shea.

Additional information about Xcelerate's R&D plans can be viewed at the newly updated www.xcelerate.global under the heading of Technology.

ABOUT XCELERATE INC.

In May 2020, Xcelerate commenced implementation of a new business plan that encompasses two separate but related businesses within the medical industry, including (i) owning and licensing the rights to various forms of medical equipment and portfolio of patents, patents pending and technology licenses and (ii) development of virtual health technology to assist patients in developing countries obtain medical care by extending the reach of physicians through the use of that technology. For more information visit www.xcelerate.global or contact us at 854-900-2020 or email info@xcelerate.global.

Rep. Liz Cheney
@RepLizCheney
I’m proud the House passed my bipartisan Advancing Telehealth Beyond COVID-19 Act & I look forward to it becoming law.

This legislation will make an important difference in Wyoming & across the country by making it easier for patients to take advantage of telehealth services.

Just sayin.........

SHOM UP 20% TWO DAYS IN A ROW. Unusually Heavy volume.
NOTE TO SELF

WHERE IS THE UPDATE? CAN'T FIND

Somebody's buying. up 25%

REVERSE: 1 FOR 400 GETS US TO NASDAQ

Form DEF 14C - filed by Altitude International Holdings, Inc.
Stocks mentioned: ALTD
Share
Listen
Save
DEF 14C 1 def14c.htm







UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549



SCHEDULE 14C INFORMATION

Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934


Check the appropriate box:

? Preliminary Information Statement
? Confidential, For Use of the Commission Only (as Permitted by Rule 14c-5(d)(2)
? Definitive Information Statement



ALTITUDE INTERNATIONAL HOLDINGS, INC.

(Name of Registrant as Specified in its Charter)



(Name of Person(s) Filing Proxy Statement, if other than the Registrant)


Payment of Filing Fee (Check the appropriate box):

? No fee required

? Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

? Fee paid previously with preliminary materials:

? Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount previously paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:













ALTITUDE INTERNATIONAL HOLDINGS, INC.

4500 SE Pine Valley Street

Port Saint Lucie, FL 34952

(772) 323-0625



July 18, 2022



To the Holders of Common Stock of Altitude International Holdings, Inc.:



This Information Statement is first being mailed on or about July 18, 2022 to the holders of record of the outstanding common stock, no par value (the “Common Stock”) of Altitude International Holdings, Inc., a New York corporation (the “Company”), as of the close of business on June 23, 2022 (the “Record Date”), to inform the stockholders of actions already approved by written consent of the majority stockholders holding approximately 50.38% of the voting power of the Company’s Common Stock. Pursuant to Rule 14c-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the proposals will not be effective until at least 20 calendar days after the mailing of this Information Statement to our stockholders, warrant holders and convertible note holders. Therefore, this Information Statement is being sent to you for informational purposes only.



WE ARE NOT ASKING YOU FOR A PROXY

AND YOU ARE REQUESTED NOT TO SEND US A PROXY



The actions to be effective at least 20 days after the mailing of this Information Statement are:


? To approve the granting of discretionary authority to the Company’s board of directors (the “Board”), at any time or times for a period of up to twelve months from the Record Date, to adopt an amendment (the “Amendment”) to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), to effect a reverse stock split (the “Reverse Stock Split”) with a ratio of up to 1 for 400 (the “Reverse Stock Split Ratio”) of the Company’s issued and outstanding shares of Common Stock.



The enclosed information statement contains information pertaining to the matters acted upon.



Pursuant to rules adopted by the Securities and Exchange Commission, you may access a copy of the information statement at https://altdintl.com.



This is not a notice of a meeting of stockholders and no stockholders’ meeting will be held to consider the matters described herein. This Information Statement is being furnished to you solely for the purpose of informing stockholders of the matters described herein pursuant to Section 14(c) of the Exchange Act and the regulations promulgated thereunder, including Regulation 14C.



ACCORDINGLY, WE ARE NOT ASKING YOU FOR A PROXY, AND YOU ARE REQUESTED NOT TO SEND US A PROXY. NO PROXY CARD HAS BEEN ENCLOSED WITH THIS INFORMATION.



This Information Statement will serve as written notice to stockholders of the Company pursuant to the Nevada Revised Statutes.


By Order of the Board of Directors.
July 18, 2022 /s/ Gregory Breunich


Gregory Breunich

Chief Executive Officer

Rudderless Shom, only direction is down.
PROVE ME WRONG MANAGEMENT

I was at at funeral in BKLYN, a week ago. should have stopped by LOL

Not quite the Blockbuster PR I was hoping for.

Where's the BEEF. that's what I wanna hear about going forward, Where will the streams of revenue be coming from. WHATS THE PLAN FOR PRICE APPRECIATION?
Look out below, because without a solid plan to hitch this stock to, this will be going back in the trips----- as Hard as it for me to type this, ----JUST SAYIN.

@DrYangSHOM
·
22m
Good morning, $SHOM share holders
Please review our new website: http://shomus.com.
News release wait for upload to OTC markets.

NEW website for SHOM, https://shomus.com/

SHELL STATUS REMOVED? Must have missed it in the PR

The Dog ate my PR


Southern Home Medical
@DrYangSHOM
·
48m
Good afternoon $SHOM share holders.
Our legal team is currently out of state and because of that they cannot approve our next PR.
We hope to publish the PR right after July 4th.
Thank you and have a good day.

When the CEO, sends smoke signals ------ on twitter. Thank him, and react accordingly.

Shareholder, if we weren't clear until now about creating share holders value, there will be NO REVERSE SPLIT nor dilution.

@DrYangSHOM
Good afternoon $SHOM shareholders.
We’re excited to get our journey started. We are working on 4 different developmental projects with a key focus on asset building.
More details early next week.
4:05 PM · Jun 22, 2022·

Must be Really, really Good News.

PATIENCE & TIME WILL TELL, OR MAYBE NOT.
Have a great weekend ----

what do yo think is causing this volume increase VF? INSIDERS keeping a secret from us?

Somebody loving this today. "Holy Volume, BATMAN"

PINK CURRENT, AGAIN. WHOOPEE!!!

STILL NO PR, LOOKING FORWARD FOR THE MONTHLY TWEET,

ANOTHER Board member added.

Cathy Scangarella to Join the Advisory Board of Xcelerate, Inc.
Mauldin, SC., June 7, 2022 --Xcelerate, Inc. (OTC Markets: "XCRT”) today announced that Cathy
Scangarella has accepted an invitation to join its Advisory Board effective immediately.
Cathy Scangarella is the Chief Business Development Officer and sector lead for Life Sciences at
Choose New Jersey, New Jersey’s leading nonprofit economic development organization. Cathy
leads the business development team and oversees the organization’s national and international
lead generation, prospect management and business development strategy for all key industries.
She also oversees the Choose New Jersey India and Europe offices and has enhanced New
Jersey’s relationships with key multipliers and trade associations around the globe.
During her tenure at Choose New Jersey, Cathy developed a new tactical business development
approach for business attraction efforts to concentrate efforts in key domestic and international
markets. She had a leading role in the strategic planning of Choose New Jersey’s business
attraction missions to Israel, Germany, Ireland, and India. While abroad, she helped established
international university collaborations and industry partnerships for many of New Jersey’s
research universities including Rutgers University, Princeton University, New Jersey City
University and Rowan University. Notable clients include Ascelia Pharma, BAP Pharma, CSL
Plasma, Fordoz Pharmaceuticals, Minerva Biolabs and Biofarma US.
Cathy is a veteran of New Jersey State government, having served six administrations. With over
25 years of experience in marketing, outreach, and business development, she has served as
Deputy Chief of Staff to Lt. Governor Guadagno, Director of State Marketing at the New Jersey
Business Action Center, Director of Outreach Programs for Business Retention & Attraction at the
New Jersey Economic Development Authority, and Vice President of Marketing &
Communications for the New Jersey Commerce Commission. Cathy is a member of the Research
With New Jersey Advisory Board, the Innovation New Jersey Coalition, and an E&Y Entrepreneur
of the Year Judge 2019-2021. She was named among the ROI-NJ Influencers: Women in Business
– Economic Development in 2021.
Cathy holds a Bachelor of Science degree in Business Administration with a concentration in
Marketing from Ramapo College of New Jersey.
“Cathy brings a valued new skill set to our Advisory Board,” said Michael O’Shea, Xcelerate’s CEO.
“Cathy’s’ experience business development, along with her years of relationships with research
institutions, should prove invaluable to Xcelerate as we begin to advance the development of the
portfolio of patents recently acquired from HS Pharmaceuticals as well as our continued
development of patentable med-tech. ”

NOW Pink
Pink Current Information
Transfer Agent Verified IconTransfer Agent Verified

Still Hope. They did the minimum effort as of this date.

Southern Home Medical
@DrYangSHOM FROM OFFICIAL TWITTER ACCOUNT
·
3h
The filing will be done soon. Sorry for the delay.

Now would be a good time to hear from company, Clock is ticking.

XCELERATE INC.
Tue, February 15, 2022, 8:30 AM·1 min read
XCELERATE INC.
XCELERATE INC.

Mauldin, SC , Feb. 15, 2022 (GLOBE NEWSWIRE) -- Xcelerate, Inc. (OTC Pink: XCRT) today announced that Fran White has accepted an invitation to join its Advisory Board effective immediately. Fran founded MDC Associates more than 30 years ago. MDC is a consulting company specializing in regulatory affairs management in the medical device and biotechnology industries. Their clients include many of the leading companies in the biotech and diagnostic industries. Prior to founding MDC, Fran held a number of management roles within ThermoFisher, a Fortune 500 world leader in the supply of scientific instrumentation, consumables and software services.

“Fran brings another invaluable skill set to our Advisory Board,” said Michael O’Shea, Xcelerate’s CEO. “Fran has more than 40 years’ experience providing companies and investors with insight to the technical and financial potential of new and existing products and technologies. This assistance will be a great enhancement to our soon to be filed series of patents developed by Dr. Anja Glisovic. Fran also has extensive experience in recognizing and getting product to market in third world countries.”

“Fran’s experience in third world markets will no doubt also be of great assistance in establishing our recently announced business opportunity in Africa through AfiyaSasa Africa, LLC” commented O’Shea. “To that end, Dr. Dilan Ellegala has been in Tanzania since the first of February working to establish the framework of the operation in that country and developing a beta program there.”

“I would like to thank our partners and investors for the continued support as we continue to execute on our business plan”

OTC: CSLI Announces Shareholder UpdatesPress Release | 12/06/2021

SHERIDAN, WY, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ?Critical? ?Solutions,? ?Inc.? ? (OTC? ?PINK:? ?CSLI)? proudly announces the continuation of “From the Boardroom” video series with multiple key announcements regarding Critical Solutions, Inc., and its holding companies. In the video Robert Munck, Vice President,? ?states,? “The company has completed the Share Exchange and consolidation of all assets from MKH Ventures into Critical Solutions providing 127% YTD gains in total asset value. Critical Solutions, Inc. has completed the stated goal of entering all three diversified high growth markets (cannabis, real estate, and crypto) that now provide significant gains to the balance sheet and help protect shareholders from potential market changes in any singular market segment. As a result of key acquisitions such as Universal Systems, Inc., and the consolidation of MKH Ventures, the company is now in communication with OTC Markets to remove the shell status and further the success of CSLI.”

PENDING POSSIBLE FUTURE ALLOCATIONS?

WHATEVER THAT MEANS,,,,,,,,,,,,,,,,,,,,